Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy

Teemu Taipale1, Kaisu Pienihäkkinen, Erika Isolauri

  • 1Korpilahti-Muurame Health Care Center, 40950 Muurame, Finland. teemu.taipale@muurame.fi

Insights

Controlled administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) probiotic in healthy infants may reduce respiratory infections. This study found fewer respiratory infections in infants receiving BB-12 compared to the placebo group.

Area of Science:

  • Microbiology
  • Pediatrics
  • Immunology

Background:

  • Probiotics, such as Bifidobacterium animalis subsp. lactis BB-12 (BB-12), are increasingly studied for their potential health benefits in infants.
  • The impact of specific probiotic strains on the incidence of acute infectious diseases in early childhood requires further investigation.

Purpose of the Study:

  • To evaluate the effect of controlled Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administration on the risk of acute infectious diseases in healthy newborn infants.
  • To assess the recovery of BB-12 in infant feces and its correlation with health outcomes.

Main Methods:

  • A double-blind, placebo-controlled study involving 109 infants aged 1-8 months.
  • Infants received either a BB-12 containing tablet or a placebo tablet twice daily via a pacifier or spoon.
  • Data collected included breastfeeding habits, infections, symptoms, and fecal samples for BB-12 quantification using qPCR.

Main Results:

  • BB-12 was detected in the feces of 62% of infants in the probiotic group.
  • No significant differences were observed in gastrointestinal symptoms, otitis media, or antibiotic use between groups.
  • Infants receiving BB-12 experienced significantly fewer respiratory infections (65%) compared to the control group (94%).

Conclusions:

  • Controlled early childhood administration of Bifidobacterium animalis subsp. lactis BB-12 may reduce the incidence of respiratory infections.
  • BB-12 supplementation appears to be a promising strategy for enhancing infant immune defenses against respiratory pathogens.

Related Concept Videos

Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
55
Microbiota of the Stomach and Small Intestine01:27

Microbiota of the Stomach and Small Intestine

The human gastrointestinal (GI) tract is characterized by distinct physicochemical conditions that shape its microbial communities. Among these, the stomach presents a particularly challenging environment for microbial colonization due to its highly acidic pH, ranging from 1 to 3. This extreme acidity effectively limits microbial density. However, certain acid-tolerant microorganisms are capable of surviving in this niche. Notably, Helicobacter pylori can colonize the gastric mucosa,...
11
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
14
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
25
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
14
Bacterial Phylum Firmicutes01:27

Bacterial Phylum Firmicutes

Firmicutes is a diverse phylum of Gram-positive bacteria characterized by a low GC content in their genomes. This phylum includes organisms with monoderm or diderm cell envelopes, highlighting a complex evolutionary history. Firmicutes comprises several major orders, including Lactobacillales, Clostridiales, and Bacillales, which exhibit remarkable diversity in their morphology, metabolism, and ecological roles.The order Lactobacillales includes lactic acid bacteria, which are fermentative...
1.3K